Affilin - Precision Targeting Technology for Multispecific Ligands - Medical / Health Care
The modular fashion with which Affilin® ligands can be fused together makes creating multi-specific binders an easy task. Combined with varying linker lengths, composition, and orientation, plus the optional addition of further accessory modules, our Navigo experts build the designed molecules as previously planned on the drawing board.
Most popular related searches
Affilin® ligands can be readily fused to the N- or C-terminus of an antibody’s heavy or light chain converting it into a bispecific format (Mabfilin™).
The ease of creating multi-specific binders with Affilin® molecules has far-reaching potential in many fields. Of particular interest is the application of multi-specific ligands for targeting cancer cells, to circumvent problems like tumor escape and antigen loss. Moreover, being small molecules (8,5kDa), multiple Affilin® sequences can be easily packed into a lentiviral system for cell surface expression, offering greater flexibility with the limited genomic space.
A classical antibody can be readily converted to a bi/multi-specific one by fusing it genetically with Affilin® molecules. Synergistically bringing together two target-binding modalities results in a Mabfilin™ Affilin®-antibody hybrid that simultaneously addresses several targets and has excellent manufacturability.
Navigo’s proprietary HER2-specific Affilin® fused C-terminally to an EGFR-specific monoclonal antibody (Cetuximab) resulted in a Mabfilin™ capable of binding both HER2 and EGFR simultaneously.